Jalandhar Online

DelveInsight’s, “Glioma Pipeline Insight, 2022,” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from Glioma Pipeline Report

• DelveInsight’s glioma pipeline report depicts a robust space with 150+ active players working to develop 150+ pipeline therapies for glioma treatment.
• Leading glioma companies such as Oncoceutics, Sumitomo Pharma, AiVita Biomedical, Denovo Biopharma, BeiGene, NEONC Technologies, AstraZeneca, Erimos Pharmaceuticals, Samus Therapeutics, GlaxoSmithKline, Symphogen, BioMimetix,  DNAtrix, NanoPharmaceuticals, Forma Therapeutics, Oblato, Nuvation Bio, Jiangsu Chia Tai Tianqing Pharmaceutical, Incyte Corporation, Prelude Therapeutics, Orgenesis, Midatech, PTC Therapeutics, Ono Pharmaceuticals, Philogen, SpringWorks Therapeutics, Xennials Therapeutics, AnHeart Therapeutics, Istari Oncology, Beijing Pearl Biotechnology, Epitopoietic Research Corporation, SonALAsense, CNS Pharmaceuticals, Adastra Pharmaceuticals, Bexion Pharmaceuticals, Inc., Merck & Co,  OncoSynergy, SystImmune, Abraxis Bioscience, Day One Biopharmaceuticals, VBL Therapeutics, Shanghai Juncell Therapeutics, Eli Lilly and Company,  Erimos Pharmaceuticals, PTC therapeutics, Candel Therapeutics, Kazia Therapeutics, Nereus Pharmaceuticals, Pfizer, Actuate Therapeutics and Kintara Therapeutics, Hutchison MediPharma, Apexigen, Mundipharma EDO, Boehringer Ingelheim, Erasca, Roche, ImmVira Pharma, Polaris Group, Taiho Oncology,  Black Diamond Therapeutics, Arcus Biosciences, Cortice Biosciences, Peloton Therapeutics, Inovio Pharmaceuticals, others are evaluating novel glioma treatment drugs candidate to improve the treatment landscape.
• Key glioma pipeline therapies in various stages of development include ONC 201, DSP-7888, AV-GBM-1, DB102, BGB-290, ,  Perillyl alcohol, Selumetinib, Terameprocol, Icapamespib, Sym004, Niraparib, ivosidenib, BMX-001, DNX-2401, fb-PMT, FT-2102, OKN-007, NUV-422, rhIL-7-hyFc, Anlotinib hydrochloride, Epacadostat, PRT811, AloCELYVIR, MTX110, SONALA-001, PTC596, Nivolumab, L19TNF, NTX-301, Mirdametinib, AB-218, PVSRIPO, PLB1001, ERC1671, Berubicin Hydrochloride, BXQ-350, TG02, Pembrolizumab, OS2966, GNC-039, ABI-009, DAY101, VB 111, Tumor Infiltrating Lymphocytes (TIL), LY2157299, PTC596 CAN-2409, CAN-3110, GDC-0084, LY3410738, PF-07799933, VAL-083,  9-ING-41, Sotigalimab , Tinostamustine, BI 907828, ERAS-801, RO7428731, C5252, ADI-PEG20, TAS2940, BDTX-1535, Sabatolimab, Afatinib, Zimberelimab, TPI 287, PT2385, INO-5401 and others.

Get an overview of the Glioma Pipeline landscape @ Glioma Emerging Therapies

Glioma Overview

Glioma is the most common form of central nervous system (CNS) neoplasm that originates from glial cells. In the United States, there are six cases of gliomas diagnosed per 100,000 people every year. Gliomas are very diffusely infiltrative tumors that affect the surrounding brain tissue. Glioblastoma is the most malignant type while pilocytic astrocytomas are the least malignant brain tumors. In the past, these diffuse gliomas were classified into different subtypes and grades based on histopathologies such as a diffuse astrocytoma, oligodendrogliomas, or mixed gliomas/oligoastrocytomas. Recently, gliomas were classified based on molecular and genetic markers. These advances have more specific prognostic and therapeutic benefits for patients with gliomas. In addition to molecular and genetic markers, gliomas are classified in grade I to IV based on the degree of proliferation indicated by the mitotic index and the presence or absence of necrosis. There are three common types of gliomas, which are classified based on the phenotypic cell characteristics: astrocytomas, ependymomas, and oligodendrogliomas.

Latest Breakthroughs of Glioma Treatment Landscape

• In June 2022, Day One announced positive initial data from the pivotal FIREFLY-1 trial of Tovorafenib (DAY101) in relapsed pediatric low-grade Glioma. Data show an overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in the first 22 evaluable patients treated with monotherapy tovorafenib. Topline results from the full FIREFLY-1 trial population are expected in Q1 2023. Day One plans to initiate a pivotal Phase 3 clinical trial of tovorafenib in front-line pediatric low-grade glioma (pLGG), with the first patient dose expected in Q3 2022.
• In June 2022, Kintara Therapeutics announced that it received fast-track designation from FDA for dianhydrogalactitol (VAL-083) for the treatment of patients with newly-diagnosed unmethylated glioblastoma (GBM). VAL-083 is a first-in-class small molecule therapeutics with a novel mechanism of action. The agent has displayed clinical activity against various cancers, including the central nervous system, ovarian, and other solid tumors.

Request a sample and discover the recent advances in Glioma Pipeline Report @ Glioma Treatment Drugs  

Glioma Emerging Drugs

• ONC 201: Chimerix
• DSP-7888: Sumitomo Dainippon Pharma
• AV-GBM-1: AIVITA Biomedical
• DB102: Denovo Biopharma
• AB-218: AnHeart Therapeutics

DelveInsight’s Glioma Pipeline Report covers around 150+ products under different phases of clinical development like-

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Learn more about the emerging Glioma pipeline therapies @ Glioma Clinical Trials

Scope of the Glioma Pipeline Report 

• Coverage: Global 
• Glioma Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Glioma Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Glioma Therapeutics Assessment By Route of Administration: Inhalation, Intranasal, Oral, Parenteral, Intravenous, Subcutaneous
• Glioma Therapeutics Assessment By Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem cell, Vaccine
• Glioma Therapeutics Assessment By Mechanism of Action: Dopamine D2 receptor antagonists,  Dopamine D3 receptor antagonists, Endopeptidase Clp stimulants, TNF-related apoptosis-inducing ligand receptor agonists, T lymphocyte stimulants, 1 Phosphatidylinositol 3 kinase inhibitors, Protein kinase C beta inhibitors, Protein-serine-threonine kinase inhibitors, Proto oncogene protein c-akt inhibitors, Immunostimulants, Isocitrate dehydrogenase 1 inhibitors, MAP kinase kinase 1 inhibitors, MAP kinase kinase 2 inhibitors, Apoptosis stimulants, BIRC5 protein inhibitors, Cdc2 kinase inhibitors, Mitosis inhibitors, Transcription factor inhibitors, Antioxidants, Sulfatase inhibitors, PRMT5 protein inhibitors, Antibody-dependent cell cytotoxicity, Raf kinase inhibitors
• Key Glioma Companies: Oncoceutics, Sumitomo Pharma, AiVita Biomedical, Denovo Biopharma, BeiGene, NEONC Technologies, AstraZeneca, Erimos Pharmaceuticals, Samus Therapeutics, GlaxoSmithKline, Symphogen, BioMimetix,  DNAtrix, NanoPharmaceuticals, Forma Therapeutics, Oblato, Nuvation Bio, Jiangsu Chia Tai Tianqing Pharmaceutical, Incyte Corporation, Prelude Therapeutics, Orgenesis, Midatech, PTC Therapeutics, Ono Pharmaceuticals, Philogen, SpringWorks Therapeutics, Xennials Therapeutics, AnHeart Therapeutics, Istari Oncology, Beijing Pearl Biotechnology, Epitopoietic Research Corporation, SonALAsense, CNS Pharmaceuticals, Adastra Pharmaceuticals, Bexion Pharmaceuticals, Inc., Merck & Co,  OncoSynergy, SystImmune, Abraxis Bioscience, Day One Biopharmaceuticals, VBL Therapeutics, Shanghai Juncell Therapeutics, Eli Lilly and Company,  Erimos Pharmaceuticals, PTC therapeutics, Candel Therapeutics, Kazia Therapeutics, Nereus Pharmaceuticals, Pfizer, Actuate Therapeutics and Kintara Therapeutics, Hutchison MediPharma, Apexigen, Mundipharma EDO, Boehringer Ingelheim, Erasca, Roche, ImmVira Pharma, Polaris Group, Taiho Oncology,  Black Diamond Therapeutics, Arcus Biosciences, Cortice Biosciences, Peloton Therapeutics, Inovio Pharmaceuticals
• Key Glioma Pipeline Therapies: ONC 201, DSP-7888, AV-GBM-1, DB102, BGB-290, Perillyl alcohol, Selumetinib, Terameprocol, Icapamespib, Sym004, Niraparib, ivosidenib, BMX-001, DNX-2401, fb-PMT, FT-2102, OKN-007, NUV-422, rhIL-7-hyFc, Anlotinib hydrochloride, Epacadostat, PRT811, AloCELYVIR, MTX110, SONALA-001, PTC596, Nivolumab, L19TNF, NTX-301, Mirdametinib, AB-218, PVSRIPO, PLB1001, ERC1671, Berubicin Hydrochloride, BXQ-350, TG02, Pembrolizumab, OS2966, GNC-039, ABI-009, DAY101, VB 111, Tumor Infiltrating Lymphocytes (TIL), LY2157299, PTC596 CAN-2409, CAN-3110, GDC-0084, LY3410738, PF-07799933, VAL-083,  9-ING-41, Sotigalimab, Tinostamustine, BI 907828, ERAS-801, RO7428731, C5252, ADI-PEG20, TAS2940, BDTX-1535, Sabatolimab, Afatinib, Zimberelimab, TPI 287, PT2385, INO-5401 and others.

Dive deep into rich insights for new drugs for Glioma treatment, visit @ Glioma Drugs

Table of Content

1. Introduction
2. Executive Summary
3. Glioma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Glioma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. VB 111: VBL Therapeutics
9. Mid Stage Products (Phase II)
10. ONC 201: Chimerix
11. Early Stage Products (Phase I)
12. Autologous tumour infiltrating lymphocytes: Shanghai Gencells Therapeutics
13. Preclinical and Discovery Stage Products
14. Autologous T-cell therapy: Kairos Pharma
15. Inactive Products
16. Glioma Key Companies
17. Glioma Key Products
18. Glioma- Unmet Needs
19. Glioma- Market Drivers and Barriers
20. Glioma- Future Perspectives and Conclusion
21. Glioma Analyst Views
22. Glioma Key Companies
23. Appendix

For further information on the Glioma pipeline therapeutics, reach out @ Glioma Treatment Landscape

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/